polici
forum
allow
health
polici
maker
around
world
discuss
challeng
opportun
improv
health
care
societi
global
hiv
vaccin
enterpris
conven
twoday
workshop
may
discuss
humor
immun
respons
hiv
approach
design
vaccin
induc
viral
neutral
potenti
protect
antibodi
respons
goal
workshop
identifi
key
scientif
issu
gap
opportun
emerg
sinc
enterpris
strateg
plan
first
publish
make
recommend
enterpris
stakehold
use
plan
new
activ
effect
viral
vaccin
work
least
part
gener
antibodi
inactiv
neutral
invad
viru
exist
data
strongli
suggest
optim
effect
vaccin
elicit
potent
antivir
neutral
antibodi
howev
unlik
acut
viral
pathogen
chronic
replic
host
evad
antibodi
respons
immun
evas
along
larg
genet
variat
among
strain
worldwid
pose
major
obstacl
vaccin
develop
current
hiv
vaccin
candid
elicit
neutral
antibodi
circul
viru
strain
thu
induct
protect
antibodi
respons
remain
major
prioriti
vaccin
develop
antibodybas
vaccin
progress
vaccin
design
gener
gaug
vitro
assay
measur
abil
vaccineinduc
antibodi
neutral
broad
spectrum
viral
isol
repres
major
genet
subtyp
clade
although
known
magnitud
breadth
neutral
predict
protect
vaccin
recipi
clear
current
vaccin
immunogen
elicit
antibodi
neutral
minor
circul
isol
thu
much
progress
need
made
area
also
though
viru
neutral
consid
critic
benchmark
vaccin
may
benchmark
predict
success
antibodybas
vaccin
immunogen
main
target
neutral
antibodi
surfac
transmembran
envelop
glycoprotein
env
mediat
receptor
coreceptor
bind
subsequ
membran
fusion
event
allow
viru
gain
entri
cell
antibodi
neutral
viru
bind
viral
spike
block
viru
entri
suscept
cell
cell
order
chronic
replic
host
viru
exploit
sever
mechan
shield
antibodi
recognit
includ
dens
outer
coat
sugar
molecul
nlink
glycan
strateg
posit
cysteinecystein
loop
structur
molecul
shield
mechan
although
highli
effect
vulner
impos
fit
constraint
inform
precis
locat
molecular
structur
vulner
region
could
valuabl
ration
design
improv
vaccin
immunogen
particip
workshop
identifi
four
area
given
proper
attent
could
provid
key
inform
would
bring
field
closer
effect
antibodybas
vaccin
structureassist
immunogen
design
role
fc
receptor
complement
assay
standard
valid
immunoregul
b
cell
respons
clinic
studi
demonstr
immun
surfac
unit
envelop
protein
lead
induct
potent
broadli
reactiv
neutral
antibodi
order
develop
better
immunogen
like
need
detail
understand
atom
level
structur
epitop
nativ
envelop
glycoprotein
data
xray
crystal
structur
ligand
unligand
partial
molecul
provid
valuabl
inform
atom
level
interact
neutral
antibodi
recent
atom
level
resolut
monoclon
antibodi
mab
bound
receptor
bind
site
molecul
provid
new
insight
success
neutral
antibodi
access
function
conserv
region
env
glycoprotein
crystal
structur
complet
monomer
trimer
complex
nativ
unligand
form
need
elucid
natur
target
neutral
antibodi
inform
need
multipl
genet
subtyp
viru
transmit
strain
viru
coupl
effort
program
make
necessari
improv
electron
tomographi
technolog
gain
higher
resolut
nativ
env
spike
exist
viru
particl
improv
understand
structur
basi
antibodi
bind
env
glycoprotein
like
form
foundat
ration
program
novel
vaccin
design
ongo
effort
stabil
immunogen
form
scaffold
conserv
neutral
epitop
foreign
protein
may
lead
promis
antibodi
respons
induct
effect
neutral
antibodi
respons
requir
vaccin
deliv
b
cell
repertoir
epitop
immunogen
ie
possess
favor
properti
b
cell
induct
pathway
antigen
ie
avail
high
affin
antibodi
bind
function
env
spike
viral
epitop
conserv
among
viral
strain
like
gener
crossreact
antibodi
regard
research
focus
small
number
human
mab
clade
b
individu
possess
broadli
crossreact
neutral
activ
cognat
viral
epitop
mab
well
character
evalu
vaccin
immunogen
howev
reason
complet
understood
conserv
viral
epitop
either
poorli
immunogen
elicit
antibodi
restrict
reactiv
improv
sought
introduc
specif
structur
alter
target
autoreact
b
cell
pathway
effort
improv
immunogen
conserv
neutral
epitop
remain
high
prioriti
workshop
particip
recogn
need
expand
effort
identifi
character
new
mab
special
attent
mab
nonclad
b
infect
new
technolog
avail
might
afford
advantag
identifi
novel
antibodi
specif
previous
undetect
addit
focu
mab
sera
select
individu
broadli
neutral
isol
studi
detail
new
assay
allow
precis
map
polyclon
antibodi
respons
sera
better
understand
epitop
target
studi
may
reveal
novel
antibodi
specif
associ
viral
epitop
could
use
immunogen
design
consider
interest
conserv
epitop
less
attent
paid
variabl
epitop
might
use
administ
form
polyval
vaccin
particular
interest
epitop
drive
autolog
neutral
antibodi
respons
infect
individu
epitop
may
quit
variabl
recent
evid
suggest
constraint
extent
variat
viru
toler
region
detail
molecular
immunolog
studi
autolog
neutral
respons
would
enhanc
understand
viral
determin
vulner
antibodi
attack
similarli
possibl
combin
antibodi
desir
addit
synergist
effect
viru
neutral
exampl
seen
solubl
bind
rearrang
structur
expos
highli
conserv
coreceptor
bind
domain
allow
antibodi
bind
viru
neutral
occur
effect
antibodi
might
discov
appli
high
throughput
screen
method
plethora
exist
mab
well
new
mab
becom
avail
futur
recent
find
gener
renew
interest
socal
nonneutr
antibodi
unabl
directli
inhibit
free
viru
entri
target
cell
nonetheless
exhibit
antivir
activ
mediat
fc
region
antibodi
molecul
antibodi
effector
mechan
includ
complement
bind
viral
lysi
phagocytosi
antibodyco
virion
antibodydepend
cellular
cytotox
recent
studi
suggest
exampl
fcdepend
antivir
effect
serum
case
littl
detect
activ
convent
neutral
assay
addit
passiv
transfer
studi
relev
monkey
model
suggest
fc
receptor
fcr
bind
capac
protect
antibodi
make
substanti
contribut
antibodymedi
protect
antibodi
effector
function
mediat
complement
activ
fcr
engag
macrophag
dendrit
cell
natur
killer
cell
cell
type
need
evalu
determin
relev
vaccin
assay
measur
antivir
antibodi
standard
use
assess
biolog
relev
passiv
protect
experi
anim
model
use
antibodi
exhibit
differ
effector
function
vitro
order
adequ
monitor
neutral
breadth
potenc
compar
priorit
immunogen
assay
need
sensit
quantit
high
throughput
correl
valu
substanti
improv
made
past
sever
year
assay
technolog
avail
refer
reagent
thu
cumbersom
expens
assay
use
peripher
blood
mononuclear
cell
pbmc
unclon
virus
replac
assay
util
molecularli
clone
envpseudotyp
virus
genet
engin
target
cell
line
new
technolog
afford
greater
sensit
reproduc
high
throughput
costeffect
compar
pbmc
assay
result
respons
explos
new
data
step
taken
collabor
aid
vaccin
discoveri
transfer
new
technolog
multipl
laboratori
around
world
implement
valid
profici
test
program
assur
interlaboratori
equival
assay
perform
recent
sever
case
identifi
neutral
consider
potent
detect
older
pbmc
assay
compar
newer
assay
technolog
rais
import
question
current
plan
employ
singl
assay
routin
use
point
need
better
understand
mechan
neutral
thu
may
necessari
use
one
assay
assur
neutral
antibodi
detect
need
standard
compar
neutral
antibodi
assay
decid
assay
combin
assay
use
standard
assess
vaccineelicit
neutral
antibodi
respons
major
prioriti
strengthen
standard
pbmc
assay
given
assay
least
partial
valid
passiv
antibodi
experi
anim
challeng
model
import
decis
need
made
type
antibodi
assay
greatest
relev
vaccin
valid
experi
anim
model
need
determin
potenti
correl
valu
new
assay
technolog
reli
use
genet
engin
cell
line
envpseudotyp
virus
ideal
would
done
employ
sever
differ
assay
studi
antibodi
respons
clinic
efficaci
trial
vaccin
least
partial
protect
vaccin
current
avail
studi
anim
model
next
best
choic
regard
two
anim
model
wide
use
hiv
vaccin
develop
simian
immunodefici
viru
siv
chimer
simianhuman
immunodefici
viru
shiv
infect
monkey
quantit
passiv
transfer
experi
either
model
antibodi
exhibit
differ
effector
function
could
use
address
biolog
relev
vitro
assay
unfortun
shiv
current
avail
among
deriv
singl
genet
subtyp
clade
b
exhibit
properti
may
well
suit
assay
valid
creation
new
better
shiv
nonclad
b
virus
would
facilit
assay
standard
well
vaccin
challeng
model
workshop
identifi
sever
critic
gap
current
understand
b
cell
regulatori
pathway
imped
ration
develop
effect
antibodybas
vaccin
exampl
broadli
neutral
antibodi
patient
serum
bind
epitop
present
monomer
yet
poor
immunogen
neutral
antibodi
induct
vaccin
recipi
moreov
mention
viral
epitop
known
broadli
neutral
mab
appear
poorli
immunogen
infect
individu
vaccin
candid
insight
immunoregul
latter
epitop
eg
epitop
defin
mab
provid
recent
studi
mab
discov
bind
one
self
antigen
rais
possibl
antibodi
specif
subject
neg
regul
mechan
receptor
edit
delet
thu
env
immunogen
may
bypass
key
step
b
cell
induct
pathway
may
activ
induc
neg
product
downregul
product
broadli
neutral
antibodi
receptorligand
interact
intracellular
signal
pathway
govern
product
antibodyproduc
plasma
cell
persist
plasma
memori
b
cell
poorli
understood
addit
inform
mechan
respons
b
cell
migrat
select
differenti
within
special
anatom
site
particularli
within
lymphoid
follicl
might
use
target
suitabl
env
epitop
appropri
b
cell
induct
pathway
exampl
would
provid
necessari
signal
gener
longliv
high
affin
memori
margin
zone
b
cell
compart
anoth
exampl
would
discov
way
modifi
germin
center
format
posit
neg
select
b
cell
differenti
drive
longliv
high
affin
antibodi
respons
key
epitop
tend
poorli
immunogen
parallel
effort
genet
studi
popul
level
could
provid
critic
inform
promis
path
follow
particular
recent
complet
intern
hapmap
project
permit
whole
genom
associ
studi
conduct
minimum
number
singl
nucleotid
polymorph
tag
power
new
technolog
could
use
identifi
gene
associ
wide
variat
neutral
antibodi
respons
individu
vaccin
recipi
critic
question
ask
whether
potent
neutral
antibodi
respons
small
subset
infect
individu
due
uniqu
viral
epitop
host
genet
polymorph
current
evid
suggest
might
make
substanti
contribut
context
combin
epitop
allel
represent
date
studi
humor
respons
hiv
infect
investig
immunoglobulin
final
product
b
cell
respons
rel
studi
examin
b
cell
immunopathogenesi
number
basic
question
still
unansw
eg
extent
reason
perturb
b
cell
subset
chang
includ
memori
b
cell
plasma
cell
peripher
blood
tissu
question
also
remain
potenti
function
contribut
b
cell
hiv
infect
eg
role
antigenpres
cell
vivo
studi
perform
nonhuman
primat
anim
model
determin
emerg
patholog
event
b
cell
compart
particular
lymphat
gastrointestin
tissu
vaccin
anim
challeng
pathogen
siv
shiv
investig
done
parallel
detail
analys
magnitud
function
hivspecif
immunoglobulin
respons
determin
plasma
tissu
secret
hivspecif
b
cell
singl
cell
basi
establish
research
consortium
studi
fundament
b
cell
biolog
relat
vaccin
recommend
program
structur
way
ask
key
scientif
question
b
cell
regulatori
pathway
modul
env
immunogen
studi
could
address
b
cell
receptorligand
interact
intracellular
signal
pathway
govern
product
antibodyproduc
plasma
cell
persist
plasma
memori
b
cell
mechan
action
adjuv
host
genet
associ
immun
respons
immun
antibodi
librari
display
yeast
yield
mani
novel
antibodi
compar
select
librari
display
phage
protein
eng
design
